Physician profile
Jeffrey Chambers
NPI 1659412245
$3,364.19
in general payments reported to CMS, 2019-2025
22 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $65.10 · 2021: $64.54 · 2022: $489 · 2023: $1,344 · 2024: $716 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.15 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $582.03 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $537.94 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $452.14 | 2023-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $355.67 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $183.81 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $177.50 | 2019-2025 | Abilify Maintena |
| Abbvie INC. | $163.75 | 2021-2025 | Vraylar |
| Allergan, INC. | $163.44 | 2019 | |
| Corium, LLC | $141.33 | 2023-2025 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $132.58 | 2022-2025 | Invega Trinza, Invega Sustenna, Spravato |
| E.R. Squibb & Sons, L.L.C. | $105.36 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $64.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.35 | 2019-2022 | |
| Shire North American Group INC | $36.75 | 2019 | |
| Bausch Health US, LLC | $36.27 | 2022-2023 | Aplenzin |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $36.11 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $35.86 | 2022-2023 | Jornay Pm |
| Almatica Pharma LLC | $29.93 | 2023-2024 | Loreev Xr |
| Tris Pharma INC | $23.81 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $22.63 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $16.92 | 2022 | |
| Neos Therapeutics, Lp | $15.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.